Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/47353
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCapkin E.-
dc.contributor.authorYazıcı A.-
dc.contributor.authorKarkucak M.-
dc.contributor.authorDurmaz Y.-
dc.contributor.authorToprak M.-
dc.contributor.authorAtaman Ş.-
dc.contributor.authorŞahin N.-
dc.contributor.authorCuzdan, Nihan-
dc.contributor.authorKasapoglu Aksoy, Meliha-
dc.contributor.authorOnder, Mustafa Erkut-
dc.contributor.authorSerdaroglu Beyazal, Munevver-
dc.contributor.authorMesci, Nilgun-
dc.contributor.authorBaykul, Merve-
dc.contributor.authorAlkan Melikoglu, Meltem-
dc.contributor.authorAlkan, Hakan-
dc.contributor.authorDulgeroglu, Deniz-
dc.contributor.authorCengiz, Ahmet Kivanc-
dc.contributor.authorNas, Kemal-
dc.contributor.authorBalevi Batur Elif-
dc.contributor.authorCaliskan Uckun, Asli-
dc.contributor.authorDeveci, Hulya-
dc.contributor.authorErol, Kemal-
dc.contributor.authorAlbayrak Gezer, Ilknur-
dc.contributor.authorAkgol, Gurkan-
dc.contributor.authorDuruoz, Mehmet Tuncay-
dc.contributor.authorKucukakkas, Okan-
dc.contributor.authorSarikaya, Selda-
dc.contributor.authorRezvani, Aylin-
dc.contributor.authorAtan, Tugba-
dc.contributor.authorGogus, Feride-
dc.contributor.authorCaglayan, Gokhan-
dc.contributor.authorKeskin, Yasar-
dc.contributor.authorBulut Keskin, Ayse Selcen-
dc.contributor.authorOz, Nuran-
dc.contributor.authorYilmaz, Gurdal-
dc.date.accessioned2023-01-09T21:24:05Z-
dc.date.available2023-01-09T21:24:05Z-
dc.date.issued2023-
dc.identifier.issn0172-8172-
dc.identifier.urihttps://doi.org/10.1007/s00296-022-05169-2-
dc.identifier.urihttps://hdl.handle.net/11499/47353-
dc.descriptionArticle; Early Accessen_US
dc.description.abstractTo evaluate of hepatitis serology and reactivation frequency in patients with rheumatic disease receiving biologic agents. Our study included patients with inflammatory rheumatic diseases from 23 centers, who were followed up with biological therapy. Demographic and clinical characteristics of the patients, duration of drug use and hepatitis serology and the state of viral reactivation were analyzed. A total of 4060 patients, 2095 being males, were included in our study. Of the patients, 2463 had Ankylosing Spondylitis (AS), 1154 had Rheumatoid Arthritis (RA), 325 had Psoriatic Arthritis (PsA), and 118 had other inflammatory rheumatic diseases. When the viral serology of the patients was evaluated, 79 patients (2%) who were identified as HBs Ag positive, 486 (12%) patients who were HBs Ag negative and anti-HBc IgG positive and 20 patients (0.5%) who were anti-HCV positive. When evaluated on a disease-by-disease basis, the rate of HBsAg was found to be 2.5% in RA, 2% in AS and 0.9% in PsA. Viral reactivation was detected in 13 patients while receiving biologic agents. HBs Ag was positive in nine patients with reactivation and negative in four patients. Anti-HBc IgG, however, was positive. Six of these patients had AS, four had RA, and three had PsA. The development of hepatitis reactivation in 11.4% of HBs Ag positive patients and 0.82% of anti-HBc IgG positive patients due to the use of biologic agents is an important problem for this group of patients. Antiviral prophylaxis is recommended to be started especially in patients who are HBs Ag positive and who are using biologic agents due to viral reactivation. Therefore, it is important to carry out hepatitis screenings before biologic agent treatment and to carefully evaluate the vaccination and prophylaxis requirements. © 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.en_US
dc.language.isoenen_US
dc.publisherSpringer Science and Business Media Deutschland GmbHen_US
dc.relation.ispartofRheumatology Internationalen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBiologic agentsen_US
dc.subjectHepatitisen_US
dc.subjectInflammatory arthritisen_US
dc.subjectViral reactivationen_US
dc.titleEvaluation of hepatitis serology and frequency of viral reactivation in patients with inflammatory arthritis receiving biologic agents: a multicenter observational studyen_US
dc.typeArticleen_US
dc.identifier.doi10.1007/s00296-022-05169-2-
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.authorscopusid10044020400-
dc.authorscopusid57879064700-
dc.authorscopusid10046031900-
dc.authorscopusid36460806300-
dc.authorscopusid36860281600-
dc.authorscopusid6602238566-
dc.authorscopusid23010163700-
dc.identifier.pmid36063169en_US
dc.identifier.scopus2-s2.0-85137505422en_US
dc.identifier.wosWOS:000849991500001en_US
dc.identifier.scopusqualityQ2-
item.openairetypeArticle-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.languageiso639-1en-
item.grantfulltextnone-
crisitem.author.dept14.02. Internal Medicine-
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Show simple item record



CORE Recommender

SCOPUSTM   
Citations

1
checked on Nov 16, 2024

WEB OF SCIENCETM
Citations

2
checked on Nov 21, 2024

Page view(s)

60
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.